Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | +3.29% | -5.12% | +9.09% |
Financials (USD)
Sales 2024 * | 4.73M | Sales 2025 * | 4.85M | Capitalization | 464M |
---|---|---|---|---|---|
Net income 2024 * | -195M | Net income 2025 * | -211M | EV / Sales 2024 * | 55.5 x |
Net cash position 2024 * | 202M | Net cash position 2025 * | 124M | EV / Sales 2025 * | 70.2 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-2.4
x | Employees | 181 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.54% |
Latest transcript on Fate Therapeutics, Inc.
1 day | +3.29% | ||
1 week | -10.13% | ||
Current month | +3.29% | ||
1 month | -44.41% | ||
3 months | -33.77% | ||
6 months | +125.41% | ||
Current year | +9.09% |
Managers | Title | Age | Since |
---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
Chairman | 75 | 11-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.95% | 1 M€ | -.--% | - | |
2.10% | 1 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 4.09 | +3.54% | 4,982,489 |
24-04-30 | 3.95 | -2.23% | 3,932,325 |
24-04-29 | 4.04 | +6.32% | 3,310,678 |
24-04-26 | 3.8 | -1.81% | 2,732,203 |
24-04-25 | 3.87 | -10.00% | 3,601,787 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.09% | 450M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- FATE Stock